Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.65. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VOOG | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $85.11 |
52-Week Low | $1.05 | $65.32 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $80.98, up 0.28% on the day. The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent news highlights its competitive expense ratio of 0.07% and heavy technology sector concentration, which has driven strong long-term returns but also introduces volatility. A 1:6 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 26, 2026.
The ETF's outlook hinges on the performance of large-cap growth stocks, particularly in technology. Opportunities exist from continued AI-driven growth, but risks include high sector concentration and market sensitivity to tech valuations. Analyst sentiment is generally positive given its low-cost structure and historical performance, though the current bearish technical signal warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
